Genocea raises $50.1M in follow-on

Genocea Biosciences Inc. (NASDAQ:GNCA) raised $50.1 million through the sale of 3.9 million shares at $13 in a follow-on underwritten by Cowen; Piper Jaffray; Stifel; and Needham. Genocea proposed the offering after market close Wednesday; it lost $1.02 to $12.89 on Thursday.

In May, six dosing combinations of Genocea's GEN-003 met the primary endpoint of a Phase II dose optimization trial to treat herpes simplex virus type 2 (HSV-2) infection. The company expects additional data this year. GEN-003 is a T cell vaccine consisting of the infected cell polypeptide 4 ( ICP4) and gD2 antigens from HSV-2 combined with the saponin-derivative adjuvant Matrix-M2. ...